Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

LisenID Says Novel Epigenetics Diagnostic Effective in Early Lung Cancer

publication date: Dec 15, 2021

Lisen Imprinting Diagnostics, a Wuxi-Philadelphia company, revealed its novel epigenetics-based diagnostic for early lung cancer detection achieved 99% sensitivity and 92% specificity in preoperative cytological diagnosis. Based on the epigenetic status of samples, the company's QCIGISH (Quantitative Chromogenic Imprinted Gene In-Situ Hybridization) technology can distinguish malignant lesions from benign tissue. The technology translates the biallelic and multiallelic expression status of cancer-related imprinted genes into visualized signals in the nuclei. The research was published in the Clinical Epigenetic Journal. More details....

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital